Small Molecule Antagonists of the CXCR2 and CXCR1 Chemokine Receptors as Therapeutic Agents for the Treatment of Inflammatory Diseases

Author(s): Jakob Busch-Petersen

Journal Name: Current Topics in Medicinal Chemistry

Volume 6 , Issue 13 , 2006

Become EABM
Become Reviewer
Call for Editor


In the past eight years, numerous series of small molecule CXCR2 and CXCR1 antagonists have been disclosed. These compounds have proved to be effective inhibitors of ELR+ chemokine-induced chemotaxis of neutrophils and other immune cells in vitro and have also been efficacious in several animal models of inflammatory disease. Although some of these compounds have been reported to be in clinical development, no data on clinical studies in patients with inflammatory disease has been revealed to date. This review details the medicinal chemistry and pharmacology of the aforementioned antagonist series.

Keywords: CXCR2, CXCR1, IL-8, GRO', neutrophil (PMN), chemotaxis, small molecule antagonist

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Published on: 01 March, 2012
Page: [1345 - 1352]
Pages: 8
DOI: 10.2174/15680266106061345
Price: $65

Article Metrics

PDF: 25